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Abstract: Despite COVID-19 turned into a pandemic, no approved drug for the treatment or globally available vaccine is out yet. In
such a global emergency, drug repurposing approach that bypasses a costly and long-time demanding drug discovery process is an effective way in search of finding drugs for the COVID-19 treatment. Recent studies showed that SARS-CoV-2 uses neuropilin-1 (NRP1)
for host entry. Here we took advantage of structural information of the NRP1 in complex with C-terminal of spike (S) protein of SARSCoV-2 to identify drugs that may inhibit NRP1 and S protein interaction. U.S. Food and Drug Administration (FDA) approved drugs
were screened using docking simulations. Among top drugs, well-tolerated drugs were selected for further analysis. Molecular dynamics
(MD) simulations of drugs-NRP1 complexes were run for 100 ns to assess the persistency of binding. MM/GBSA calculations from
MD simulations showed that eltrombopag, glimepiride, sitagliptin, dutasteride, and ergotamine stably and strongly bind to NRP1. In
silico Alanine scanning analysis revealed that Tyr297, Trp301, and Tyr353 amino acids of NRP1 are critical for drug binding. Validating the
effect of drugs analyzed in this paper by experimental studies and clinical trials will expedite the drug discovery process for COVID-19.
Key words: SARS-CoV-2, COVID-19, NRP1, drug repositioning, eltrombopag, sitagliptin

1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infected over 40 million people and resulted
in more than 1.5 million deaths around the world
since December 2019.1 The coronavirus disease-2019
(COVID-19) has symptoms of pneumonia manifesting
fever, fatigue, dyspnea, chest pain, and cough which are
also observed in other viral respiratory diseases (Yi et al.,
2020). The whole-genome analysis showed that SARSCoV-2 belongs to the Betacoronovirus genera and has a 96%
genomic sequence identity to that of bat coronavirus (Wu
et al., 2020b; Zhou et al., 2020). Despite the high genomic
similarities, SARS-CoV-2 behaves more aggressively than
SARS-CoV in terms of viral load, reaching the peak RNA
concentration, tissue tropism, and transmission efficiency
(Wolfel et al., 2020).
SARS-CoV-2 genome is composed of a (+) sense
single-strand RNA (ssRNA) with 14 open reading frames
(ORFs). SARS-CoV-2 synthesizes two polyproteins,
ORF1a and ORF1ab, and four structural proteins e.g.,
spike (S), envelop (E), matrix (M), and nucleocapsid (N)
1
Worldometers (2020). COVID-19 Coronavirus Pandemic [online].
Website: https://www.worldometers.info/coronavirus/ [accessed 05
December 2020].

proteins and accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b,
and orf14) (Wu et al., 2020a; Yoshimoto, 2020). Proteolytic
cleavage of ORF1a and ORF1ab by proteases leads to the
production of 16 nonstructural proteins (nsps). Among
nsps, nsp5 (3C-like protease, 3CLpro) first cleaves its bounds
with nsp4 and nsp6, then cleaves the ORF1a and ORF1ab
at 11 sites (Du et al., 2004; Muramatsu et al., 2013). Besides
3CLpro, nsp3 (papain-like protease, PLpro) cleaves these
polyproteins at three sites and completes the production
of 16 nsps (Baez-Santos et al., 2015; Thiel et al., 2003).
S protein of SARS-CoV-2 interacts with angiotensinconverting enzyme 2 (ACE2) that has been accepted as
the main receptor for the entry of the virus (Wang et al.,
2020; Yan et al., 2020). ACE2, a membrane protein, is
expressed in lung, upper and stratified epithelial cells of the
esophagus, heart, kidney, testis, colon, ileum, and intestine
(Donoghue et al., 2000; Zhang et al., 2020). Despite the
attenuated expression of ACE2 in elderly people, increased
or unaffected severity of COVID-19 symptoms (Walls et
al., 2020) in these people (Liu et al., 2020; Omori et al.,
2020; Singh et al., 2020a), and high viral loads in the throat
(Wolfel et al., 2020) suggest the existence of an alternative
receptor for the virus entry.
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A polybasic sequence (Arg682Arg-Ala-Arg685) at the S1/
S2 region of S protein of the SARS-CoV-2 may explain its
higher transmission rate and tissue tropism. This sequence
is also conserved in the S protein of various pathogenic
human viruses such as Ebola, influenza, and HIV-1 (Tse
et al., 2014). Cleavage of the S protein within the polybasic
sequence, which is primed by transmembrane serine
protease 2 (TMPRSS2) via furin produces S1 and S2
(Hoffmann et al., 2020b). FURIN mediated cleavage of S
protein results in increased tropism and the infection rate
of SARS-CoV-2, most probably because of the formation
of new cell surface binding regions (Hoffmann et al., 2020a;
Wrapp et al., 2020). Knocking down FURIN gene or using
its inhibitor decreases the virus entry to cells and syncytia
formation in the infected cells, respectively (Shang et al.,
2020; Walls et al., 2020).
(Arg682Arg-Ala-Arg685) sequence is aligned with
[R/K]XX[R/K] motif (R: arginine, K: lysine, and X is
any amino acid), named as C-end rule (CendR). CendR
binds and activates cell surface receptors neuropilin
(NRP1,2) (Teesalu et al., 2009). NRP1 binds to several
growth factors such as vascular endothelial growth factors
(VEGFs) (Soker et al., 1998), hepatocyte growth factor
(Sulpice et al., 2008), and transforming growth factor (Cao
et al., 2010). Among those, the interaction between NRP1
and VEGF-A165 has been extensively studied ( Teesalu et
al., 2009; Jarvis et al., 2010; Parker et al., 2012; Fantin et
al., 2014; Jia et al., 2014; Mota et al., 2018; Powell et al.,
2018). C-terminal arginine residue and CendR motif of
VEGF-A165 critically interact with b1 domain of NRP1
(NRP1-b1) in which natural and artificial NRP1 inhibitors
were explored (Vander Kooi et al., 2007). Having a cavity
on CendR binding pocket of NRP1 made it an attractive
target for designing small-molecules. Several molecules
blocking NRP1-VEGF interaction were developed (Jarvis
et al., 2010; Powell et al., 2018). First designed NRP1
inhibitor, EG00229, occupied the VEGF-A binding region
by directly interacting with Tyr297, Glu348, Thr349, and Tyr353
(Jarvis et al., 2010). Based on the discovered scaffold
of EG00229, a more potent molecule, EG01377 was
developed (Powell et al., 2018). Both these molecules bind
to NRP1 with a very similar mode.
Recent studies showed that interaction between NRP1
and protein S of SARS-CoV-2 is required for the SARSCoV-2 cell entry (Cantuti-Castelvetri et al., 2020; Daly
et al., 2020). While coexpression of NRP1 with ACE2
and TMRPSS2 increased the infection, monoclonal
antibody targeting the b1b2 extracellular domain of NRP1
significantly inhibited the infection. The stimulating effect
of NRP1 on the virus infection diminished when the
furin cleavage site of SARS-CoV-2 is mutated (CantutiCastelvetri et al., 2020). Analysis of direct interaction

between CendR peptide of protein S and NRP1 using
isothermal titration calorimetry method showed that
binding affinity of the complex is between 20 and 13µM
depending on the pH. Mutating the critical arginine
residue (Arg685) on the CendR of protein S prevented the
NRP1 binding (Daly et al., 2020). The crystallographic
analysis confirmed that the binding mode of protein S’
CendR to the NRP1 is similar to the previously resolved
NRP1-VEGF-A structure (Daly et al., 2020; Parker et al.,
2012).
To date, there is no consensus on the treatment of
COVID-19 yet. Since developing a new drug is costly
and requiring a long period, repurposing of U.S. Food
and Drug Administration (FDA) approved drugs may
provide an alternative approach to find a therapeutic
for the COVID-19 treatment within a reasonable time
and cost. Multiple targets are available to neutralize
COVID-19. For example, virus entry proteins on the host
(ACE2, TMPRSS2, NRP1), replication machinery of the
virus (3CLpro RNA-dependent RNA polymerase), virus
proteins taking roles on the assembly mechanism (protein
E) and the release of the virus (protein M and N) are
candidates for drug development and drug repurposing (
Venkatagopalan et al., 2015; Schoeman and Fielding, 2019;
Li et al., 2020a; Sarma et al., 2020). Given the crucial role of
NRP1 for the SARS-CoV-2 entry into the host specifically
in elderly people, this in silico study aimed to repurpose
FDA-approved drugs against b1 domain of NRP1 to
find a promising drug to block SARS-CoV-2 infection.
For this purpose, initially docking simulations were run
to find drugs with high binding affinity to b1 domain of
NRP1. As a control, previously identified NRP1 inhibitor,
EG01377, was docked to the same pocket. While docking
binding energy of the inhibitor is around –6.0 kcal/mol,
over 250 drugs have –7.4kcal/mol or lower AutoDock
Vina binding energy. Drugs were sorted based on docking
binding energies, and an extensive literature search was
done to select well-tolerated drugs for further analysis.
One hundred ns molecular dynamics simulations (MD)
of drug-NRP1 complexes showed that thrombopoietin
receptor agonist eltrombopag, migraine drug ergotamine,
drugs for type 2 diabetes sitagliptin and glimepiride, and
antiandrogen dutasteride can stably interact with NRP1.
Crystal structure of NRP1 in complex with EG01377 (PDB
ID: 6FMF) was simulated to compare the affinity of selected
drugs with its inhibitor. Binding free energy calculation
using MM/GBSA method showed that selected drugs have
a comparable or better affinity to NRP1 than EG01377.
Alanine scanning calculations revealed Tyr297, Trp301, and
Tyr353 as the critical amino acid residues for drug-NRP1
interaction. These findings may be used in experimental
studies and clinical trials to test the effect of promising
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drugs alone or in combination with current COVID-19
treatment protocols.
2. Materials and methods
High-resolution human NRP1 structure (PDB ID: 6FMC)
was retrieved from The Protein Data Bank2 (Powell et
al., 2018). Protein was prepared for docking simulations
via Dock Prep module of UCSF Chimera as described
previously ( Tardu et al., 2016; Doruk et al., 2020; Gul et
al., 2020). Crystal water molecules were removed and if
alternate locations are available for residues, the ones with
the higher occupancies were selected. Rotamer library
developed by Shapovalov and Dunbrack (2011) was used
to complete missing side chains of amino acids, polar
hydrogens were added, and nonpolar hydrogens were
merged with bound atoms. Atom charges should be defined
to run docking simulations. Thus, Gasteiger charges to each
atom in the protein were assigned using Auto Dock Tools
(ADT) (v. 1.5.6). Structures of drugs were downloaded
from Zinc15 database catalogue of FDA-approved drugs.
Set of drugs used in this study were imported from the
U.S. Environmental Protection Agency’s (EPA) distributed
structure-searchable toxicity (DSSTox) database. The 3948
drugs and NRP1 inhibitor (EG01377) were prepared for
docking by using ADT suite. Inhibitor binding pocket of
NRP1 was targeted for docking simulations in which grid
center was placed on the center of Tyr297, Glu348, and Tyr353
side chains with 6400 Å3 of the grid box. AutoDock Vina
(version 1.1.2) was used for the docking (Trott and Olson,
2010).
With the aid of VMD, NRP1 structure (PDB ID: 6FMF)
was solvated using TIP3P water molecules in a rectangular
box with edge lengths of x = 75 Å, y = 80 Å, z = 75 Å and
a size of 4.50 × 105 Å3. Solvated protein was neutralized
and then ionized with sodium-chloride salt (Na+ and Cl-)
to 150 mM final concentration to mimic the physiological
conditions (Humphrey et al., 1996). Twenty thousand
steps of energy minimization (via conjugate gradient) was
performed. The minimized system was gradually heated
and then equilibrated for 1.4 ns (NPT ensemble) with
constraints on the protein. Constrains starting from 2
kcal/mol/Å2 were reduced by 0.5 kcal/mol/Å2 for each 0.4
ns equilibration run. Production simulation of 100 ns for
each equilibrated drug-NRP1 complex was run using 2 fs
time step at 310K and 1atm pressure. Langevin thermostat
and Langevin barostat maintained the temperature and
pressure, respectively. To calculate the force acting on
the system van der Waals (12Å cut-off) and long-range
electrostatic interactions (via particle-mesh Ewald) were
RCSB PDB (Research Collaboratory for Structural Bioinformatics
PDB) (2021). The Protein Data Bank [online]. Website www.rcsb.org
[accessed 18 September 2020].
2
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calculated. NAMD (Phillips et al., 2005) software and
CHARMM36m force field (Huang et al., 2017) were used
for all MD simulations. CHARMM-GUI server was used
to generate parameters of drugs (Jo et al., 2008; Kim et al.,
2017).
Analyses of protein-drug interactions were done by
following these steps: 1) MD trajectory of each drugprotein simulation was visualized to inspect the position
of the drug. If the drug leaves the binding pocket, that
one is eliminated. 2) For simulations that drug-protein
interaction was maintained for 100 ns, root mean square
deviation (RMSD) of Cα atoms was calculated to verify
the successful equilibration of the system. 3) Contact
frequency between drug and nearby amino acid residues
were carried out for determining the binding residues.
4) Binding free energy (BFE) of drugs was calculated
using molecular mechanics generalized born surface area
(MM/GBSA) method. 5) Amino acid residue with a high
contact frequency was mutated to Alanine to calculate
their contribution to BFE of drugs. All MD analyses
were performed and protein figures were prepared by
using VMD and Pymol, respectively (Humphrey et al.,
1996; DeLano, 2009). RMSD trajectory tool and timeline
function in VMD were used to calculate RMSD of protein
and contact frequencies between drug and protein,
respectively. Unstructured and highly dynamic first 9
N-terminal amino acid residues were excluded from the
RMSD calculation.
For MM/GBSA and Alanine scanning calculations,
MMPBSA.py script of AmberTools20 was used (Case et
al., 2020). For each calculation, 25,000 frames from 100 ns
simulations were used. BFE between drug and protein is
calculated based on Equation 1:
ΔGbinding = Gcomplex – Greceptor – Gligand (1)
Gcomplex : Energy of protein-drug complex,
Greceptor : Energy of protein only,
Gligand : Energy of unbound drug.
3. Results
To discover an antiviral drug diverse targets are available
from viral replication enzymes to host proteins facilitating
the virus entry and to proteins responsible for the virus
release (Boopathi et al., 2020; Lo et al., 2020; Wu et
al.,2020b). Several in silico and in vivo drug repurposing
studies are carried out using proteases (3CLpro and PLpro)
and RNA-dependent RNA polymerase (RdRp) of SARSCoV-2 as targets (Bharadwaj et al., 2020; Ghosh et al., 2020;
Gul et al., 2020; Li et al., 2020c; Wang, 2020). In addition,
host proteins TMPRSS2 and ACE2 which primes protein
S and mediates SARS-CoV-2 entry to host, respectively,
are targeted for drug repositioning as well (Bagheri and
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Niavarani, 2020; Busnadiego et al., 2020; Carino et al.,
2020; Choudhary et al., 2020; DurdaGi, 2020; Kumar et al.,
2020; Singh et al., 2020b).
NRP1 is a recently identified receptor that facilitates
the SARS-CoV-2 cell entry in coordination with ACE2
and TMPRSS2 (Cantuti-Castelvetri et al., 2020; Daly et
al., 2020). S protein of SARS-CoV-2 attaches to the host
cells for the virus entry (Wang et al., 2020; Yan et al., 2020).
When the S protein is cleaved by the host protease, S1 and
S2 proteins are generated. S1 has a polybasic sequence
(Arg682-Arg-Ala-Arg685) at the C-terminal which interacts
with b1 domain of NRP1 (Cantuti-Castelvetri et al., 2020;
Daly et al., 2020) (Figure 1). Mutating the critical Arg685
diminishes protein S and NRP1 binding (Daly et al., 2020)
and antibody against b1b2 domain of NRP1 relieve the
SARS-CoV-2 infection (Cantuti-Castelvetri et al., 2020).
Drugs having a high affinity to CendR binding pocket of
NRP1 can be used in the COVID-19 treatment by blocking
SARS-CoV-2 entry into cells.
3.1. Docking simulations
AutoDock Vina program was used to calculate binding
energy and predict the binding mode of drugs to the target
pocket as described before (Tardu et al., 2016; Gul et al.,
2020). During the docking simulations, receptor (NRP1)
was treated as a rigid body and drugs were allowed to
sample different conformations in the CendR binding

pocket. NRP1 inhibitor, EG01377 (Powell et al., 2018),
was docked to NRP1 as a control to evaluate the binding
affinities of drugs against NRP1. Vina binding energy of
EG01377 was calculated as –6.0 kcal/mol (Table 1). The
docked conformation of EG01377 is in contact with Tyr297,
Trp301, Lys351, and Tyr353 similar to observed in the crystal
structure (6FMF) (Figure 2A). Docking simulations
revealed that over 100 molecules have Vina binding
energies –7.6 kcal/mol or lower (Table S1). Histogram
representation of Vina binding energies of all drugs are
provided in (Figure S1). Top 15 of those drugs having the
Vina binding energies between –8.5 and –8.0 kcal/mol
were given in (Table 1) with their ZINC IDs, structures,
and types.
Docking simulations showed that, according to
the descriptions in DrugBank (Wishart et al., 2006),
various types of drugs such as anticancer, antipsychotics,
antiinflammatory, antibiotics, antidiabetics, and estrogen
hormone may bind to NRP1 (Table S1). For further
analysis, widely used drugs eltrombopag (–8.5 kcal/mol),
glimepiride (–8.2 kcal/mol), dutasteride (–8.2 kcal/mol),
sitagliptin (–8.2 kcal/mol), ergotamine (-8.1 kcal/mol)
at the top of the docking result list, and two antimalarial
drugs, mefloquine (–8.0 kcal/mol) and atovaquone (–7.9
kcal/mol), having similar binding energies to top drugs
were selected. Two-dimensional diagram of interaction

Figure 1. Structure of NRP1 in complex with polybasic peptide at the C-terminal of protein S (PDB ID: 7JJC). NRP1 is shown in cartoon
at left critical residues are shown in ball and sticks (cyan color), polybasic peptide is shown in ball and sticks (gray color) representation.
NRP1 is shown in surface representation at right.
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Table 1. List of top 15 drugs having the best binding affinity to NRP1 inhibitors.
ZINC ID and/or
drug name

2D Structure

Vina binding affinity
Type
(kcal/mol)

ZINC000011679756/
Eltrombopag

–8.5

Thrombopoietin
receptor agonist

ZINC000003830767/
Estradiol benzoate

–8.5

Estrogenic steroids

ZINC000064033452/
Lumacaftor

–8.4

Used to treat fibrosis
(CF) in patients having
homozygous F508del
mutation in their CFTR
gene.

ZINC000011681563/
Netupitant

–8.3

Antiemetic

ZINC000000006157/
Epinastine

–8.3

Antiallergic

ZINC000000002070/
Sorbinil

–8.3

Inhibitor of aldose
reductase

ZINC000000537791/
Glimepiride

–8.2

Antidiabetics
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Table 1. (Continued.)
ZINC ID and/or
drug name

2D Structure

Vina binding affinity
Type
(kcal/mol)

ZINC000003932831/
Dutasteride

–8.2

Antiandrogen

ZINC000001489478/
Sitagliptin

–8.2

Antidiabetics

ZINC000000004724/
Trileptal

–8.2

Antiepileptic

ZINC000001996117/
Darifenacin

–8.1

Treats urinary
incontinence

ZINC000052955754/
Ergotamine

–8.1

Antimigraine

ZINC000003831448/
Silibinin

–8.1

Anticancer and various
pharmacological effect
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Table 1. (Continued.)
ZINC ID and/or
drug name

2D Structure

Vina binding affinity
Type
(kcal/mol)

ZINC000003978005/
Dihydroergotamine

–8.0

Antimigraine

ZINC000003869855/
Dicumarol

–8.0

Anticoagulant

EG01377

–6.0

Inhibitor of NRP1

pattern of EG01377 in the crystal showed that it can
generate hydrogen bond, or interact via van der Waals
or pi interactions with Asp320, Ile415, Thr316, Gly414, Tyr353,
Lys351, Ser346, Thr349, Tyr297, Ser298, Trp301, Glu348, and
Asn300 (Figure 2B). Among those, hydrogen bond and pi
interactions between the inhibitor and Tyr297, Tyr353, and
Trp301; and van der Waals interactions generated through
Ser298, Ser346, Thr316, Ile415, Gly414, Thr349, Lys351, and Asn300
were reproduced in docking pose as well. However, some
hydrogen bond and pi interactions between the inhibitor
and amino acids such as inhibitor-Asp320 and Glu348 in
the crystal could not be observed in the docking pose.
Hydrogen bond interactions between the inhibitor and
Ser298, Thr349, Ser346 in the crystal were generated as van der
Waals type interaction in docking conformation (Figure
2C). Note that to compare docking position of EG01377
with that of in crystal, structure with 6FMF PDB ID was
used since the binding mode of inhibitor in 6FMF was
stated as free of artifact in the original study (Powell et
al., 2018). To solidify the idea of using NRP1 inhibitor
as an antiviral drug, the binding mode of S protein to
NRP1 was analyzed (Daly et al., 2020) and compared with
that of EG01377. The peptide of S protein interacts with
Asp320, Tyr297, Trp301, Thr349, Lys351, Tyr353, and Ser346 of
NRP1 via either of hydrogen bond, pi, and van der Waals
interactions. Interaction between EG01377 and all of these
amino acids shows that NRP1 inhibitor has the potential
to be an antiviral drug. Furthermore, the binding poses of
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selected drugs occupy the pocket surrounded by Tyr297,
Trp301, Lys351, and Tyr353 in docking simulations which
supports the idea of these drugs may behave as NRP1
inhibitors (Figures 2D and 2E). To evaluate the persistency
and strength of drug-NRP1 complexes near physiological
conditions, MD simulations were run.
3.2. MD simulations and binding free energy calculation
In short MD simulations (20 ns) eltrombopag, glimepiride,
dutasteride, sitagliptin, and ergotamine stably interacted
with NRP1, however, atovaquone and mefloquine did
not. These two antimalarial drugs left their initial docking
positions and moved to the solution even in two independent
trials. Then we extended 20 ns simulations for those who
could interact with the protein in these short simulations
to 100 ns to assess the stability of their interaction with
NRP1. In a control simulation, the EG01377-NRP1
complex obtained from crystal (6FMF) was simulated for
100 ns. Visual inspection of long simulations showed that
all selected drugs and the inhibitor retained their docking
positions on the NRP1 through the entire simulation.
Root mean square deviation analysis (RMSD) of Cα atoms
showed that simulations reached equilibrium around 2Å
after an initial jump within 1–2 ns (Figure 3).
To examine the interaction between drugs and
critical residues, the contact frequency between drugs
and selected amino acids around the binding pocket
were visualized. Thus, the persistency of drug-amino

GÜL / Turk J Biol

Figure 2. (A) Binding of EG01377 (shown in sticks representation) in the crystal (PDB ID: 6FMF) (carbon atoms are shown
in green) in the docking simulation (carbon atoms are shown in white) to b1 domain of NRP1 (shown in white cartoon
representation). (B) 2D interaction diagram of EG01377 binding to NRP1 in crystal structure (6FMF). (C) 2D interaction
diagram of EG01377 in docking simulation. Diagrams were generated by using Discovery Studio Visualizer. (D) Binding mode
of eltrombopag, glimepiride, dutasteride, sitagliptin, and ergotamine to NRP1 obtained from the docking. (E) Binding of two
antimalarial drugs mefloquine and atovaquone to NRP1 obtained from the docking.

Figure 3. Root mean square deviation (RMSD) of Cα atoms in drug-NRP1 simulations.

acid interactions observed in the initial docking position
could be assessed (Figures 4A–4F). Docking of EG01377
showed that the inhibitor interacts with Tyr297, Trp301,
Thr316, Glu348, Thr349, Lys351, Tyr353. In MD simulations,
EG01377 interacted frequently with Tyr297, Trp301, Thr316,
and Tyr353 which have aromatic (Tyr and Trp) and polar
(Thr) side chains. In addition to these highly interacting
amino acids, the inhibitor interacted with Glu348 and Thr349

through 100 ns simulation (Figure 4A). As a result, MD
simulation of EG01377-NRP1 analysis verified interacting
residues in the docking. Contact frequency analysis for
eltrombopag-NRP1 simulation indicated that similar to
EG01377, Tyr297, Trp301, Thr316, and Tyr353 are the frequently
interacting residues. The same residues were also identified
in docking simulation (Figure 4B). In addition to these
highly interacting amino acids, interaction between Asp320
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and eltrombopag that is identified in the EG01377-NRP1
crystal structure (6FMF) makes eltrombopag drug a prime
candidate. One minor difference between EG01377 and
eltrombopag simulations is that while EG01377 interacted
with Gly318, eltrombopag interacted more with Gly414.
Glimepiride and sitagliptin frequently interacted with
the same amino acids that are Tyr297, Trp301, Thr316, Thr349,
and Tyr353 (Figures 4C and 4E) in MD simulations. To note
some interactions altered throughout the simulations. For
example, interaction with highly interacting amino acids
Thr349 and Lys351 fluctuated as simulations progressed.
Despite slight differences in their docking positions,
interacting residues in docking simulations are very
similar. While glimepiride interacted with Tyr297, Trp301,
Thr316, Glu348, Thr349, and Tyr353, sitagliptin fitted a deeper
part of the pocket and, in addition to glimepiride’s
interacting amino acids, interacted with Thr316 (Figures
4C and 4E). Overall, nearby residues observed in docking
simulations of glimepiride and sitagliptin were verified by
MD simulations.
The docking position of dutasteride showed that the
drug interacts with Tyr297, Thr349, Lys351, and Tyr353. MD

simulation of dutasteride-NRP1 showed that dutasteride
behaved less similarly with the inhibitor and did not
interact with Trp301 and Tyr353 after a certain time (Figure
4D). Possibly dutasteride translated in the binding pocket
and started to interact with new residues such as Gly318,
Glu319, Asp320, and Ile415.
Ergotamine showed similar interaction frequency
patterns with the inhibitor and constantly interacted with
Tyr297, Trp301, Thr316, and Tyr353 (Figure 4F). In addition
to these, ergotamine interacted with Asp320, Thr349, and
Ile415 in certain periods of the MD simulation. In docking
simulation ergotamine interacted with Tyr297, Trp301,
Thr316, Ser346, Glu348, Thr349, Lys351, and Tyr353. While some
of the amino acids recognized in the docking lost contact
with ergotamine such as Ser346 and Glu348, most of them
interacted with ergotamine in the whole MD simulation.
To determine the binding free energy (BFE) between
drugs and NRP1 MM/GBSA method was used. The BFE
of eltrombopag, glimepiride, dutasteride, sitagliptin,
and ergotamine was calculated as –17.11, –12.55, –9.47,
–13.34, and –14.95 kcal/mol, respectively (Table 2). BFE of
EG01377 was calculated as –16.19 kcal/mol.

Figure 4. The binding pose in docking simulations and interaction frequency of amino acids from 100 ns MD simulations for NRP1 in
complex with (A) EG01377, (B) eltrombopag, (C) glimepiride, (D) dutasteride, (E) sitagliptin, (F) ergotamine.
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Table 2. MM/GBSA BFE of selected drugs
and NRP1 inhibitor.
Drug name

MM/ GBSA BFE (kcal/mol)

Eltrombopag –17.11 ± 2.99
Ergotamine

–14.95 ± 7.40

Sitagliptin

–13.34 ± 3.90

Glimepiride

–12.55 ± 3.48

Dutasteride

–9.47 ± 4.41

EG01377

–16.19 ± 4.20

A well-tolerated drug eltrombopag stimulates platelet
synthesis in patients having low blood platelet (EricksonMiller et al., 2009). In comparison to EG01377, eltrombopag
has comparable Vina binding energy (–8.5 kcal/mol) and
BFE (–17.11 kcal/mol) calculated from docking and MD
simulations, respectively. During the MD simulations
interacting residues of EG01377 and eltrombopag with
NRP1 are very similar to each other (Figure 4B). A
previous drug-repurposing study against 3CLpro and RdRp
of SARS-CoV-2 from our group showed that eltrombopag
may bind to the active site of 3CLpro and nsp8 binding site
of RdRp which may attenuate the virus activity (Gul et al.,
2020). Eltrombopag exhibits in vitro antiviral properties
with IC50 lower than 10µM (Jeon et al., 2020). This report
shows that eltrombopag can strongly interact with NRP1,
as well. If these in silico findings can be verified by in vitro
and cell-culture experiments, eltrombopag can be a very
strong antiviral drug by blocking SARS-CoV-2-NRP1
binding to host and alleviating the virus replication.
Two antidiabetics, glimepiride and sitagliptin are welltolerated drugs used to treat type2 diabetes (Bautista et
al., 2003; Raz et al., 2008). Both drugs have the same Vina
binding energies (–8.2 kcal) in docking simulations and
very similar BFEs calculated from MM/GBSA analysis
that are –13.34 and –12.55 kcal/mol for sitagliptin
and glimepiride, respectively. Interacting amino acid
residues and BFEs of these antidiabetics are quite alike to
EG01377 (Figures 4C and 4E). Sitagliptin is an inhibitor of
dipeptidyl-peptidase IV (DPP-4) that is the host receptor
of the Middle East respiratory syndrome (MERS)-CoV
(Karasik et al., 2008; Raj et al., 2013) and in silico studies
suggested that protein S of SARS-CoV-2 can bind to DPP4
as well (Li et al., 2020b; Vankadari and Wilce, 2020).
Administration of sitagliptin to patients suffering from
diabetes and COVID-19 does not only help to lower the
blood glucose level but may also reduce the SARS-CoV-2
entry to the cells.
Dutasteride, another well-tolerated drug, inhibits type
I and II 5α-reductase and shows antiandrogenic activity
(Roehrborn et al., 2002; Andriole and Kirby, 2003).

5α-reductase converts testosterone to dihydrotestosterone
and enlarges the prostate glands. Thus, dutasteride is used
to treat prostatic conditions by blocking the 5α-reductase
activity (Makridakis et al., 2000). Besides the effect on the
prostate gland, dutasteride suppresses the transmembrane
serine protease 2 (TMPRSS2) expression (Mostaghel et
al., 2014) which primes protein S of the SARS-CoV-2
(Hoffmann et al., 2020b). Docking binding energy and
MM/GBSA calculations show that dutasteride has a high
affinity to NRP1 (Tables 1 and 2). Relatively higher BFE
with a high standard deviation of dutasteride-NRP1 may
stem from the loss of interaction between dutasteride and
two aromatic residues Trp301 and Tyr353 as shown in contact
frequency analysis (Figure 4D). However, dutasteride has
still a high affinity to the NRP1 and interacts with amino
acids observed in docking simulations. Despite further in
vivo analysis needed, dutasteride may be a preventive drug
that shuts down the virus entry by blocking the NRP1 and
downregulating the TMPRSS2.
Antimigraine ergotamine is a tolerable drug with mild
and transient side effects (Diener et al., 2002; Christie et al.,
2003). Several in silico drug repurposing studies reported
that ergotamine may inhibit the RdRp and 3CLpro of SARSCoV-2 (Barage et al., 2020; Gul et al., 2020). Ergotamine
has the second-best BFE among all drugs analyzed in
this study (Table 2). Comparable BFEs of ergotamine
and EG01377 to NRP1 suggests that ergotamine can
strongly bind to NRP1, in turn, can attenuate NRP1protein S binding. If these computational analyses can
be experimentally verified, ergotamine can be used to
mitigate the COVID-19. To note, it has been reported
that ergotamine may cross-react with antiviral drugs
(Rosenthal et al., 1999; Mortier et al., 2001; Ayarragaray,
2014). Thus, further studies related to ergotamine should
be designed accordingly.
Comparable BFE and interaction pattern of inhibitor
and selected drugs indicate that these drugs may act as
NRP1 inhibitors.
3.3. H-bond and Alanine scanning analysis
To determine the number of hydrogen bonds drug made
during the MD simulation, the hydrogen bond (H-bond)
generated by drugs to any amino acids through 100 ns were
analyzed (Figure 5). Calculation of the average number of
H-bonds showed that each drug, including the inhibitor,
produced less than one H-bond per frame. Interaction
types between selected drugs and protein were analyzed
and represented in a two-dimensional diagram (Figure 6).
Analyses showed that the inhibitor and all drugs interact
with the protein through hydrophobic interactions,
and conduct hydrogen bond and at least one type of pi
interaction. Since drugs of interest possess aromatic rings,
charged or aromatic amino acids on NRP1 generate those
interactions. Tyr297 consistently generated pi interactions,

451

GÜL / Turk J Biol
Trp301 and Tyr353 have generated either H-bond or pi
interactions with all drugs. Ser298, Thr316, Glu348, and Gly414
interacted with drugs through van der Waals interactions
and generated hydrophobic interactions. Ser298 formed
hydrogen bonds only with EG01377 and ergotamine.
Glu348 generated pi interactions and hydrogen bonds with
EG01377 and glimepiride, and only pi interactions with
eltrombopag.
Despite drugs suggested to behave like NRP1 inhibitor
have diverse structures, they have some common
properties. For example, all drugs analyzed in details
have multiple ring structures at least one with aromatic.
Second, all these organic compounds bear polar groups
such as carbonyl group or halogen atoms that have ability
to generate hydrogen bonds or pi interactions with amino
acids. Third, drugs have 70 to 110 atoms in their structure
that allow them to generate high number of van der Waals
interaction with the protein. These common properties of
drugs cause tight binding to NRP1.

Figure 5. H-bond analysis of each drug/inhibitor made to NRP1
(per frame) in MD simulation. A total of 25,000 frames (every
4ps) were included for this calculation.

Figure 6. Two-dimensional diagram of interaction type between NRP1 in complex with (A) EG01377 in crystal structure (6FMF), or
(B) eltrombopag, (C) glimepiride, (D) dutasteride, (E) sitagliptin, (F) ergotamine obtained from docking simulations.
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To reveal the critical amino acids for drug binding
and quantify their contribution to BFE, in silico Alanine
scanning mutation was performed. The most frequently
and commonly interacting amino acids e.g., Tyr297, Trp301,
Thr316, and Tyr353 in all drug/inhibitor-NRP1 simulations
were analyzed (Figures 4A–4F). These residues were
mutated to Alanine one by one and BFE between drugs
and NRP1 was calculated using the MM/GBSA method
(Table 3). Then the difference between BFEs of drugs
against mutant and wild-type NRP1 is calculated
(ΔΔG). ΔΔG values larger than 0 means that mutation
is destabilizing the interaction, ΔΔG lower than 0 means
mutation is stabilizing the interaction. Free energy change
in protein-protein interaction at equilibrium is calculated
by using the following formula: ΔGᵒ = –RTlnKeq where ΔGᵒ
is the standard free energy change, R is the gas constant,
T is the absolute temperature. Using R = 1.987 × 10-3
kcal/mol, T = 298 K in that formula gives that increase
in 0.4–0.5 kcal/mol in ΔGᵒ (ΔΔG in our data), leads
to 2-fold decrease in ligand bound protein state. Thus,
mutations causing ΔΔG > 0.5 kcal/mol were evaluated as
critical amino acid for drug-protein binding. According
to ΔΔG values, Tyr297, Trp301, and Tyr353 are very critical
for all drugs binding to NRP1. Interestingly, despite high
interaction with drugs, Thr316 minimally contributes to
BFE. Tyr297 has the highest contribution to BFE, –4.03,
–4.12, –2.24 kcal/mol, in NRP1-EG01377, eltrombopag,
and dutasteride simulations, respectively. Trp301 is the
second highest contributor to BFE in EG01377 (–3.1 kcal/
mol), eltrombopag (–2.36 kcal/mol), and sitagliptin (–2.60
kcal/mol) simulations and top contributor to BFE in
ergotamine-NRP1 simulation (–2.43 kcal/mol). Tyr353 has
a similar effect on the binding of eltrombopag to NRP1
with Trp301 and contributes –2.37 kcal/mol to BFE. Tyr353
has also the highest effect on BFE in sitagliptin (–3.06 kcal/
mol) and glimepiride (–2.39 kcal/mol) simulations. (Table
3). The contribution of each mutated amino acid to drugNRP1 BFE is given (Figure 7).

H-bond and Alanine scanning calculations provide a
deeper understanding of drug-NRP1 interactions. Future
structure-activity relationship (SAR) studies aim to design
a more potent NRP1 inhibitor may benefit from the critical
amino acids identified here. Adding an H-bond donor
or acceptor to a new molecule can increase the binding
affinity to NRP1.
4. Conclusion
Despite substantial progress has been made by several
companies for the SARS-CoV-2 vaccine (Corbett et al.,
2020; Mulligan et al., 2020; Sahin et al., 2020) only several
governments approved for emergency use authorization.
Therefore, medication is still an essential element to
combat COVID-19. Vital enzymes of SARS-CoV-2 such as
proteases (3CLpro and Mpro) and RNA polymerase (RdRp),
or virus binding receptors on the host such as ACE2 or
TMPRSS2 are generally targeted in drug repurposing
studies (Bagheri and Niavarani, 2020; Busnadiego et al.,
2020; Carino et al., 2020; Gul et al., 2020; Kumar et al.,
2020; Li et al., 2020c; Singh et al., 2020b). Recent studies
reported protein S binds to NRP1 which facilitates SARSCoV-2 host entry (Cantuti-Castelvetri et al., 2020; Daly et
al., 2020). Here a drug repurposing study was done against
NRP1 in terms of docking and MD simulations using
the FDA approved drugs. Furthermore, key amino acids
on NRP1 for drug binding were identified by running
Alanine scanning analysis. Several well-tolerated drugs
showed comparable and even better affinity to NRP1
than its inhibitor EG01377. Eltrombopag had the best
binding affinity to NRP1 among all drugs. In addition to
eltrombopag, two antidiabetics, sitagliptin and glimepiride
stably interacted with and exhibited high affinity to NRP1.
Since patients having chronic diseases such as diabetes
are at more risk against COVID-19, those suffering from
diabetes may benefit from sitagliptin and glimepiride
not only as antidiabetics but also their preventive effects,
if proven by experiment, against SARS-CoV-2 infection.

Table 3. MM/GBSA BFE after Alanine mutations of selected residues.
BFE (kcal/mol)
Mutations Drugs Y297A/ΔΔG W301A/ΔΔG T316A/ΔΔG Y353A/ΔΔG
Eltrombopag

–12.99/4.12

–14.75/2.36

–16.65/0.46

–14.74/2.37

Ergotamine

–12.77/2.18

–12.52/2.43

–14.63/0.32

–13.41/1.54

Sitagliptin

–11.56/1.78

–10.74/2.60

–12.79/0.55

–10.28/3.06

Glimepiride

–11.27/1.28

–11.51/1.04

–12.65/–0.10 –10.16/ 2.39

Dutasteride

–7.23/2.24

–8.84/0.63

–9.23/0.24

–8.72/0.75

EG01377

–12.16/4.03

–13.09/3.1

–15.44/0.75

–14.03/2.16
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Figure 7. Contribution of critical residues to BFE in drug-NRP1binding.

Dutasteride may provide multiple benefits to COVID-19
patients. First, it reduces the expression of TMPRSS2 that
primes the S-protein (Hoffmann et al., 2020a; Hoffmann
et al., 2020b). Second, in silico studies reported that it may
block 3CLpro (Gul et al., 2020). Third, this study shows that
dutasteride can bind to and strongly interact with NRP1,
thus, may decrease SARS-CoV-2 entry. Ergotamine is
another top candidate molecule for the NRP1 binding.
Previous calculations showed that ergotamine has the
potential to bind to 3CLpro and RdRp of SARS-CoV-2 (Gul
et al., 2020; Rahman et al., 2020). Therefore, ergotamine
may inhibit SARS-CoV-2 at the infection and replication
stages. Alanine scanning calculations uncovered that
Tyr297, Trp301, and Tyr353 are the most critical amino acid
residues for drug binding to NRP1. H-bond analysis and
Alanine scanning results may be exploited by further
inhibitor design studies.
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To expedite the discovery of therapeutics for COVID-19
drug repurposing studies may provide a rational starting
point. If the findings of this study can be verified by in
vitro, in vivo, and clinical trials these well-tolerated and
cost-effective drugs can be adapted to current protocols
used to treat COVID-19.
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Table S1. Top 100 drugs from docking simulations.
Vina binding
energy
ZINC ID
(kcal/mol)

Drug name

–8.5

ZINC000011679756 Eltrombopag

–8.5

ZINC000003830767 Estradiol benzoate

–8.5

ZINC000019632618 Imatinib

–8.4

ZINC000064033452 Lumacaftor

–8.4

ZINC000011681563 Netupitant

–8.4

ZINC000036701290 Ponatinib

–8.3

ZINC000000006157 Epinastine

–8.3

ZINC000000002070 Sorbinil

–8.2

ZINC000000537791 Glimepiride

–8.2

ZINC000003932831 Dutasteride

–8.2

ZINC000001489478 Sitagliptin

–8.2

ZINC000000004724 Trileptal

–8.1

ZINC000001996117 Darifenacin

–8.1

ZINC000052955754 Ergotamine

–8.1

ZINC000002032615 Permethrin

–8.1

ZINC000003831448 Silibinin

–8

ZINC000000119978 Catechin

–8

ZINC000003869855 Dicumarol

Usage
Used to treat low blood platelet counts in adults with chronic immune
(idiopathic) thrombocytopenia (ITP)
Act as the major female sex hormone
A small molecule kinase inhibitor used to treat certain types of cancer.
Used for the management of Cystic Fibrosis (CF) in patients aged 6 years
and older.
An antiemitic drug used in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer
chemotherapy
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially
effective against the T315I mutation for the treatment of chronic myeloid
leukemia.
Used for the prevention of itching associated with allergic conjunctivitis.
Aldose reductase inhibitor
Used for the management of type 2 diabetes mellitus (T2DM) to improve
glycemic control.
Novel dual 5α-reductase inhibitor that works by blocking both isoforms
of 5α-reductase enzymes in a potent, selective, and irreversible manner.
A Dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with
diet and exercise to improve glycemic control in patients with type 2
diabetes mellitus
An antiepileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000
Used to treat urinary incontinence.
Alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
A pyrethroid insecticide commonly used in the treatment of lice infestations and scabies.
Has hepatoprotective (antihepatotoxic) properties that protect liver cells
against toxins.
An antioxidant flavonoid

–7.9

Interferes with the metabolism of vitamin K.
A 9,10alpha-dihydro derivative of ergotamine. It is used as a vasoconZINC000003978005 Dihydroergotamine
strictor, specifically for the therapy of migraine disorders.
Flubendazole is an anthelmintic that is used to treat worm infection in
ZINC000003830847 Flubendazole
humans.
ZINC000000897089 Mefloquine
A phospholipid-interacting antimalarial drug.
Use in combination with cisplatin for the treatment of patients with maZINC000001540998 Pemetrexed
lignant pleural mesothelioma
ZINC000002510358 Phenytoin
One of the most commonly used anticonvulsants.
An antineoplastic agent used off-label for lung cancer, breast cancer, and
ZINC000001539579 Targretin
Kaposi’s sarcoma.
A hydroxynaphthoquinone, or an analog of ubiquinone, that has antimiZINC000012504271 Atovaquone
crobial and antipneumocystis activity.
ZINC000003830772 Estradiol cypionate Major female sex hormone.

–7.9

ZINC000003824921 Fexofenadine

Antihistamine used in the treatment of various allergic symptoms

–7.9

ZINC000002036732 Florantyrone

Florantyrone is used in the treatment of biliary dyskinesia

–8
–8
–8
–8
–8
–8
–7.9
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Table S1. (Continued.)
Vina binding
energy
ZINC ID
(kcal/mol)

Drug name

Usage
A nonsteroidal antiinflammatory agent (NSAIA) with analgesic and
antipyretic properties
A broad- spectrum beta-lactam antibiotic
Acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules.
A semisynthetic antibiotic related to penicillin
A potent, highly selective, long-acting neurokinin-1 (NK-1) receptor
antagonist
Used to control seizures and to treat pain resulting from trigeminal neuralgia
An oral leukotriene receptor antagonist (LTRA) for the maintenance
treatment of asthma
A nonergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson’s.
A serotonin antagonist and a histamine H1 blocker used as antipruritic

–7.9

ZINC000000002272 Ketoprofen

–7.9

ZINC000003831159 Latamoxef

–7.9

ZINC000000121541 Mebendazole

–7.9

ZINC000003831169 Nafcillin

–7.9

ZINC000003816514 Rolapitant

–7.9

ZINC000000004785 Tegretol

–7.8

ZINC000000896717 Zafirlukast

–7.8

ZINC000000009073 Apomorphine

–7.8

ZINC000000968264 Cyproheptadine

–7.8

ZINC000003830628 Danazol

–7.8

ZINC000003830765 Estradiol

–7.8

ZINC000003939013 Fosaprepitant

A synthetic steroid with antigonadotropic and antiestrogenic activities
Estradiol is a naturally occurring hormone circulating endogenously in
females.
An intravenously administered antiemetic drug.

–7.8

ZINC000005162311 Ilevro

A nonsteroidal antiinflammatory prodrug (NSAID)

–7.8

ZINC000000002279 Ketorolac

A nonsteroidal antiinflammatory drug (NSAID)

–7.8

ZINC000003831231 Novobiocin

An antibiotic compound derived from Streptomyces niveus.

–7.8

ZINC000000897253 Olopatadine

–7.8

ZINC000004175630 Pimozide

–7.8

ZINC000000538658 Tolvaptan

–7.8

ZINC000006745272 Regorafenib

Selective histamine H1 antagonist and mast cell stabilizer
An antipsychotic agent, alternative to haloperidol for the suppression of
vocal and motor tics in patients with Tourette syndrome.
Used to treat low blood sodium levels (hyponatremia) associated with
various conditions
Regorafenib is an orally-administered inhibitor of multiple kinases.

–7.8

ZINC000000020253 Thalitone

A thiazide-like diuretic used for the treatment of hypertension

–7.7

ZINC000003830716 Diphenoxylate

A meperidine congener used as an antidiarrheal

–7.7

ZINC000027428713 Aprepitant

–7.7

ZINC000000537795 Glipizide

–7.7

ZINC000019796080 Droperidol

–7.7

ZINC000001550477 Lapatinib

An antiemetic, P/neurokinin 1 (NK1) receptor antagonist
An oral hypoglycemic agent, used to control blood sugar levels in patients with type 2 diabetes mellitus.
Used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia
An anticancer drug

–7.7

ZINC000000000509 Mirtazapine

–7.7

ZINC000004213946 Nebivolol

–7.7

ZINC000001481956 Paliperidone

–7.7

ZINC000003819392 Riociguat

–7.7

ZINC000001493878 Sorafenib

–7.7

ZINC000004475353 Sulindac

–7.7

ZINC000003831615 Zeranol

2

A tetracyclic piperazino-azepine antidepressant agent
A racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic
activity.
The primary active metabolite of risperidone
A soluble guanylate cyclase (sGC) agonist
Used for the treatment of advanced renal cell carcinoma (primary kidney
cancer).
A nonsteroidal antiinflammatory drug (NSAID) of the arylalkanoic acid
class
A nonsteroidal estrogen agonist.
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Table S1. (Continued.)
Vina binding
energy
ZINC ID
Drug name
(kcal/mol)
–7.7
ZINC000000538550 Ziprasidone

Usage
Atypical antipsychotics, used to treat schizophrenia and bipolar disorder

–7.6

ZINC000002568036 Dantrolene

A hydantoin derivative but does not exhibit antiepileptic activity

–7.6

ZINC000000403011 Labetalol

–7.6

ZINC000053151228 Methysergide

–7.6

ZINC000001530977 Naftifine

–7.6

ZINC000084589076 Warfarin

–7.6

ZINC000000523926 Gliclazide

–7.6

ZINC000003831490 Sulfasalazine

–7.6

ZINC000001530596 Cephalexin

–7.6

ZINC000001552174 Cilostazol

–7.6

ZINC000000402909 Fenoprofen

–7.6

ZINC000000537877 Ketanserin

–7.6

ZINC000003830435 Ceforanide

Used to treat hypertension
An ergot derivative that antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle
A synthetic, broad spectrum, antifungal agent
An anticoagulant drug normally used to prevent blood clot formation as
well as migration.
Used for the treatment of noninsulin-dependent diabetes mellitus (NIDDM).
Used in the management of inflammatory bowel diseases.
Used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis
Quinolinone derivative and antiplatelet agent with vasodilating properties
An antiinflammatory analgesic and antipyretic highly bound to plasma
proteins.
Investigated for the treatment of septic shock, severe sepsis, and diabetic
foot ulcer.
Second-generation cephalosporin antibiotic

–7.6

ZINC000058581064 Dolutegravir

–7.6

HIV-1 intergrase inhibitor
Naturally occurring hormone circulating endogenously in females. Used
Estradiol TransderZINC000013520815
in several hormone therapy products for managing conditions associated
mal Patch
with reduced estrogen
ZINC000000000903 Alprazolam
Used for the treatment of anxiety and panic disorders.

–7.6

ZINC000000538505 Trifluperidol

Experimental

–7.6

ZINC000001997125 Pomalidomide

–7.6

ZINC000053683151 Bromocriptine

–7.6

ZINC000003802417 Alvimopan

An immunomodulatory antineoplastic agent
A semisynthetic ergot alkaloid derivative with potent dopaminergic activity.
Peripherally acting μ opioid antagonist.

–7.6

ZINC000000537804 Glisoxepide

sulphonamide-derived oral antidiabetic drug

–7.6

ZINC000009212426 Leucovorin

–7.6

ZINC000001481983 Benzoctamine

–7.6

ZINC000001612996 Irinotecan

–7.6

ZINC000000968337 Azatadine

–7.6

ZINC000019632668 Doxapram

A necessary cofactor in the body.
Used as a sedative which does not depress the respiratory system, but
rather stimulates it.
Anticancer
Antihistamines to compete with histamine for histamine H1- receptor
sites on effector cells.
A central respiratory stimulant with a brief duration of action

–7.6

ZINC000003830594 Dicloxacillin

One of the penicillins which is resistant to penicillinase

–7.6

ZINC000003830401 Cefatrizine

–7.6

ZINC000068202099 Sonidegib

–7.6

ZINC000000057321 Fenoterol

–7.5

ZINC000000086535 Flufenamic acid

–7.5

ZINC000018067894 Acetohexamid

Experimental
A Hedgehog signaling pathway inhibitor developed as an anticancer
agent.
An adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.
An anthranilic acid derivative with analgesic, antiinflammatory, and
antipyretic properties.
A sulfonylurea hypoglycemic agent

–7.6
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Vina binding
energy
ZINC ID
(kcal/mol)

Drug name

–7.5

ZINC000000897225 Hidroflumetiazid

–7.5

ZINC000043207238 Canagliflozin

–7.5

ZINC000000897408 Bicalutamide

–7.5

ZINC000000004893 Asenapine

–7.5

ZINC000035342789 Tolcapone

–7.5

ZINC000019796168 Sildenafil

–7.5

ZINC000003830836 Doxepin
HydroxystilbamiZINC000000001547
dine isethionate

–7.5

4

Usage
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide
A sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus
An oral nonsteroidal antiandrogen for prostate cancer.
Atypical antipsychotic for treatment of schizophrenia and acute mania
associated with bipolar disorder.
Used in the treatment of Parkinson’s disease as an adjunct to levodopa/
carbidopa medication.
Prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5
(PDE5) pulmonary hypertension
A psychotropic agent with antidepressant and anxiolytic properties
Used in the therapy of some patients with nonprogressive blastomycosis
of the skin, and pulmonary or systemic blastomycosis in children
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Figure S1. Vina binding energies of all drugs to NRP1.
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